Pinar Bailey, Ph.D.

Associate, Intellectual Property  

Mountain View 650.335.7965


Pinar Bailey focuses her practice on technology-based commercial transactions, including intellectual property acquisitions and licensing; patent prosecution; patent portfolio analysis; and intellectual property due diligence for clients in the life sciences and high technology industries. Pinar also advises clients on intellectual property matters associated with corporate transactions. She combines a deep scientific and technical background with thorough legal analysis to counsel clients in intellectual property matters presenting novel legal challenges that frequently arise from cutting edge emerging technologies. 

Pinar’s representative transactions include: development, collaboration, license, supply, and service agreements and software agreements, including click-through online agreements and privacy policies. In her patent work, Pinar handles complex cross-over technologies touching on biotechnology.

Prior to joining Fenwick & West, Pinar was a patent agent in the Intellectual Property Counseling & Patents Group at Wilson Sonsini Goodrich & Rosati, PC in Palo Alto. Since 2011, she has managed patent portfolios of biotechnology companies in a wide range of technical fields including gene sequencing, gene synthesis, microfluidics, gene therapy, personalized medicine, bioinformatics, and machine learning.

Pinar received her J.D. from Stanford Law School in 2016, her Ph.D. in Biophysics from the University of California San Francisco in 2010 and her B.S. in Molecular Biology & Genetics and Physics from Bogazici University in 2000, as class valedictorian. While at Stanford Law School, she was the recipient of the Gerald Gunther Prize for Outstanding Performance in Intellectual Property and the John Hart Ely Prize for Outstanding Performance in Intellectual Property and Antitrust Law. At UCSF, she was the recipient of Howard Hughes Medical Institute Predoctoral Fellowship.


  • Digital Health Companies May Find a Faster Path to Market Under the FDA’s Digital Health Plan, Life Sciences Legal Insights Blog, August 2017
  • Transactions Triggering the 35 USC §102 On-Sale Bar, Intellectual Property Strategist, July 2017